Navigation Links
3-drug combination 'extremely promising' as first-line therapy for multiple myeloma
Date:12/11/2007

ATLANTAA new combination of bortezomib (Velcade) and two other drugs is showing a very high response rate in patients newly diagnosed with multiple myeloma, a team headed by Dana-Farber Cancer Institute investigators reported at the annual meeting of the American Society of Hematology.

The three-pronged regimen of Velcade, lenalidomide (Revlimid) and dexamethasone referred to as Rev/Vel/Dex has achieved an overall response rate of 98 percent in 42 patients evaluated thus far in a Phase 1-2 trial, said Paul Richardson, MD, of Dana-Farber and the studys principal investigator. He added that 52 percent of the patients had high quality responses (very good partial response or better), with 30 percent achieving complete response to date.

These may be some of the best response rates weve seen to date with up-front therapies, and although these are preliminary results, they are extremely promising, Richardson said. The patients were previously untreated when they received the Rev/Vel/Dex combination.

Velcade is a smart drug known as a proteasome inhibitor that blocks the myeloma cells waste disposal system, creating an accumulation of toxic compounds that poison the cell. Revlimid is a chemical relative of thalidomide that affects several pathways in cancer cells, including immune mechanisms and blood vessel growth to tumors. Dexamethasone is a steroid hormone that counters inflammation and is used to treat hematologic malignancies such as myeloma. Studies leading to the trial of the three drugs in combination were carried out at Dana-Farber.

While these are the first results from trials of Rev/Vel/Dex given as initial, first-line therapy for the blood cancer, the combination has already been shown effective for multiple myeloma patients who had relapsed following successful treatment or who had not responded to standard therapies.

Richardson also reported at the ASH meeting preliminary data from a Dana-Farber led mul
'/>"/>

Contact: Teresa Herbert
617-632-4090
Dana-Farber Cancer Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Promising drug combination may help those with ocular melanoma that has spread
2. Combination therapy reverses effects of portal hypertension in rats
3. Combination vaccines okay for infants, study shows
4. Antidepressants and painkillers - a dangerous combination
5. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
6. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
7. Drug combination might offer hope for patients deadly brain tumors
8. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
9. Combination targets: some drugs may work best when they work together
10. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
11. Quality Control: Nissan Quest to Feature micronAir(R) Combination Cabin Air Filters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... To help healthcare organizations ... practices compliantly and profitably, MDreferralPRO and Vericle ... The interoperability between a strategic referral management ... management system is necessary for a healthcare ... referral management and development solution relies on ...
(Date:3/1/2015)... Orion, Metamora, Michigan (PRWEB) March 01, 2015 ... is approved to treat Overactive Bladder (OAB) symptoms, such as ... in adults when another type of medication (anticholinergic) does not ... a different treatment option that takes another approach to targeting ... , BOTOX® works on the nerves and bladder muscle, blocking ...
(Date:3/1/2015)... 01, 2015 A federal court ... ) scheduled to go to trial in October ... witness to provide testimony regarding the role an ... the Profemur device, Bernstein Liebhard LLP comments. According ... Northern District of Iowa on February 25th, Wright ...
(Date:3/1/2015)... GA (PRWEB) March 01, 2015 ... Evelyn King and Carolyn Roddy to the professional staff ... of Compliance, graduated from The Ohio State University-Mortiz College ... 15 years of experience working with several Fortune 500 ... in the area of corporate benefits. Her experiences range ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The MCA ... across Malaysia into one platform and gears towards the ... , A series of group talks in smaller groups ... Nation Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, Social ... raise awareness of Malaysian youths. , Young ...
Breaking Medicine News(10 mins):Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 2Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 3Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 4Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4
... Programming Kit and Software ,Separately From its Hearing Aids For the ... ... 2008 -- America Hears, Inc. , the leading online supplier ... of its hearing-aid programming software, Virtual Office, and announced it will ...
... and Cubicin is Driven Strongly by Agents, ... Report from AMR and Decision,Resources, MALVERN, ... Resources (AMR) and Decision Resources find that ... by methicillin-resistant Staphylococcus,aureus (MRSA), an overwhelming majority ...
... health threat, especially in underdeveloped areas , , TUESDAY, ... but neglected threat to global public health, new research ... PLoS Medicine , estimates that at least 421,000 ... suggesting the numbers could be as much as four ...
... Will Be Featured at ASN, EL SEGUNDO, ... of kidney care services for those diagnosed with ... Research(R) (DCR),recently contributed fifteen abstracts to the 41st ... of Nephrology. These,abstracts were developed both internally and ...
... media outlets ran stories about Dr. Sanford Siegal,s, ... October 30th, MIAMI, Nov. 4 Last ... ran stories on renowned physician, author,and weight loss ... Dr.,Siegal,s COOKIE DIET(R) weight loss system and hunger-controlling ...
... (TSX: RBM, OTCBB: RPBIF) today announced that S. Wayne ... Renshaw 10th Annual,Healthcare Conference on Tuesday, November 11 at ... in New York City., A Web cast of ... the event and will be,archived and available on a ...
Cached Medicine News:Health News:America Hears Introduces New and Improved Hearing-Aid Programming Software 2Health News:America Hears Introduces New and Improved Hearing-Aid Programming Software 3Health News:Activity Against MRSA is the Most Important Attribute Influencing Physicians' Antibiotic Selection for the Treatment of Skin and Skin Structure Infections 2Health News:Activity Against MRSA is the Most Important Attribute Influencing Physicians' Antibiotic Selection for the Treatment of Skin and Skin Structure Infections 3Health News:DaVita Abstracts Accepted into American Society of Nephrology Meeting 2Health News:DaVita Abstracts Accepted into American Society of Nephrology Meeting 3Health News:DaVita Abstracts Accepted into American Society of Nephrology Meeting 4Health News:Media Spotlight Shines on Dr. Siegal's Cookie Diet While Major Study Reveals Doubling of U.S. Type II Diabetes Cases During Past Ten Years 2Health News:Media Spotlight Shines on Dr. Siegal's Cookie Diet While Major Study Reveals Doubling of U.S. Type II Diabetes Cases During Past Ten Years 3Health News:Response Biomedical to Present at Rodman and Renshaw 10th Annual Healthcare Conference 2
(Date:3/2/2015)... 2015   , Boston Scientific to ... consideration of up to $1.65 billion, with $1.6 billion in ... alternatives for AMS, Women,s Health business , ... business Endo International plc (NASDAQ: ... into a definitive agreement with Boston Scientific (NYSE: ...
(Date:3/2/2015)...  BioMed Realty Trust, Inc. (NYSE: BMR ... feet of space in the most dynamic and valuable ... the termination of Vertex Pharmaceuticals, leases on three properties ... 28, 2015. BioMed Realty will receive a $14 million ... reposition the properties to meet the growing demand for ...
(Date:3/1/2015)... , March 1, 2015  An innovative interventional ... migraine sufferers sustained relief of their headaches, according ... of Interventional Radiology ,s Annual Scientific Meeting ... State University New York Empire State College in ... sphenopalatine ganglion (SPG) blocks to give patients enough ...
Breaking Medicine Technology:Endo Announces Divestiture of American Medical Systems' Men's and Prostate Health Businesses to Boston Scientific 2Endo Announces Divestiture of American Medical Systems' Men's and Prostate Health Businesses to Boston Scientific 3BioMed Realty Gets Back 313,000 Square Feet Of Valuable Real Estate In Cambridge Innovation District 2BioMed Realty Gets Back 313,000 Square Feet Of Valuable Real Estate In Cambridge Innovation District 3Image-guided treatment shown to break the migraine cycle 2Image-guided treatment shown to break the migraine cycle 3Image-guided treatment shown to break the migraine cycle 4
... of Proprietary siRNA Molecule in Acute ... ... Inc., a,development-stage pharmaceutical company focused on discovering and,developing novel RNA interference-based ... its proprietary product,candidate, AKIi-5, a siRNA compound discovered and developed by ...
... 16 AstraZeneca (NYSE:,AZN) today announced that the ... SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release,Tablets for maintenance treatment ... the FDA approved SEROQUEL XR for the acute ... experience high rates of symptom relapse, and as,a ...
Cached Medicine Technology:Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 2Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 3Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 4SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 2SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 3SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 4SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 5SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 6SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 7SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 8
Phaco-emulsification systems CV series...
The unprecedented power, flexibility and versatility of the Series 20000 Legacy have made it the world's leading phacoemulsifier....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....
Medicine Products: